Form 4: OrbiMed's Carl Gordon Increases Stake in MBX Biosciences Through Open Market Purchases
SEC Form 4 Filing
Carl Gordon, a director and 10% owner of MBX Biosciences, has increased his indirect holdings through open market purchases of common stock, executed via OrbiMed funds.
Summary
- Carl Gordon, a director and 10% owner of MBX Biosciences, has reported changes in beneficial ownership.
- The transactions involved the purchase of MBX Biosciences' common stock through OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P.
- On February 14, 2025, 17,962 shares were purchased at a weighted average price of $9.90, and 29,540 shares were purchased at a weighted average price of $9.85.
- On February 18, 2025, 49,070 shares and 94,100 shares were purchased at a weighted average price of $10.84.
- Following these transactions, the total number of shares indirectly beneficially owned by Mr. Gordon through OrbiMed Private Investments VII, LP is 3,255,000 and through OrbiMed Genesis Master Fund, L.P. is 747,887.
- Mr. Gordon disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed as a positive sign, but the filing itself is a routine regulatory disclosure.
Positives
- The director's purchase of shares could be interpreted as a positive signal about the company's prospects.
- Increased ownership aligns the director's interests more closely with those of other shareholders.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of insiders. These filings are closely watched by investors seeking insights into management's confidence in the company's future prospects.
Stakeholder Impact
- Shareholders may view the insider buying as a positive signal.
- The increased ownership aligns the director's interests more closely with those of other shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Purchase of 17,962 shares of common stock at a weighted average price of $9.90. |
| 02/14/2025 | Purchase of 29,540 shares of common stock at a weighted average price of $9.85. |
| 02/18/2025 | Purchase of 49,070 shares of common stock at a weighted average price of $10.84. |
| 02/18/2025 | Purchase of 94,100 shares of common stock at a weighted average price of $10.84. |
| 02/19/2025 | Date of signature for the Form 4 filing. |
Keywords
MBX Biosciences, Carl Gordon, OrbiMed, Beneficial Ownership, Form 4, Insider Trading, Stock Purchase
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.